Euro vs US Dollar

Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.

Registrieren

KTTAW Pasithea Therapeutics Corporation

0,0178

0,00 (0,00%)

Vor Marktöffnung

Zuletzt aktualisiert: 13:00:00

Verzögert um 15 Minuten

Form ARS - Annual Report to Security Holders

Pasithea Therapeutics (NASDAQ:KTTAW)
Historical Stock Chart
Von Jun 2024 bis Jul 2024

Click Here for more Pasithea Therapeutics Charts.

Pasithea Therapeutics (NASDAQ:KTTAW)
Historical Stock Chart
Von Jul 2023 bis Jul 2024

Click Here for more Pasithea Therapeutics Charts.

News Pasithea Therapeutics Corporation

Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for PAS-004 in Ongoing Phase 1 Clinical Trial
Donnerstag 13 Juni 2024 (1 Monat vor) • GlobeNewswire Inc.

Form ARS - Annual Report to Security Holders
Dienstag 28 Mai 2024 (2 Monate vor) • Edgar (US Regulatory)

Form DEF 14A - Other definitive proxy statements
Dienstag 28 Mai 2024 (2 Monate vor) • Edgar (US Regulatory)

Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting
Dienstag 28 Mai 2024 (2 Monate vor) • GlobeNewswire Inc.

Form 8-K - Current report
Dienstag 14 Mai 2024 (2 Monate vor) • Edgar (US Regulatory)

Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting
Montag 29 April 2024 (3 Monate vor) • GlobeNewswire Inc.

Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers
Mittwoch 24 April 2024 (3 Monate vor) • GlobeNewswire Inc.

Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004
Dienstag 13 Februar 2024 (5 Monate vor) • GlobeNewswire Inc.

Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position
Montag 8 Januar 2024 (6 Monate vor) • GlobeNewswire Inc.

Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients
Dienstag 2 Januar 2024 (6 Monate vor) • GlobeNewswire Inc.

Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023
Donnerstag 28 Dezember 2023 (7 Monate vor) • GlobeNewswire Inc.

Pasithea Therapeutics Announces Results from 2023 Annual Meeting
Dienstag 19 Dezember 2023 (7 Monate vor) • GlobeNewswire Inc.

Weitere Pasithea Therapeutics Corporation News-Artikel

Wld Sri Eur Acc

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen